| 教員紹介トップページへ | 三重大学トップページへ |
| 職名 | 助教 | |||||||||
| 氏名 | 重福 隆太 |
|||||||||
| 生年月 | ||||||||||
|
||||||||||
| TEL | 059-231-9238 | |||||||||
| FAX | 059-231-5269 | |||||||||
| shigefuku@med.mie-u.ac.jp | ||||||||||
| 個人のホームページ | ||||||||||
| 学歴 | ||||||||||
| 学位 | 2012年 博士（医学） | |||||||||
| 所属学会 | 日本内科学会
日本消化器病学会 日本肝臓学会 日本消化器内視鏡学会 日本門脈圧亢進症学会 日本消化管学会 アルコール医学生物学研究会 日本がん治療認定医機構 |
|||||||||
| 社会活動 | ||||||||||
| 職歴 | ||||||||||
| 学術（芸術）賞 | 2015年9月 日本門脈圧亢進症学会 第1回 田尻賞（和文原著部門）
2017年9月 日本門脈圧亢進症学会 第24回総会 最優秀演題賞 2019年9月 日本門脈圧亢進症学会 第5回 田尻賞（和文症例報告部門） |
|||||||||
| 専門分野 | 肝臓病 | |||||||||
| 現在の研究課題 | 肝硬変・門脈圧亢進症・肝細胞癌 等 | |||||||||
| 担当科目 | ||||||||||
| 主な業績等 | 1.Shigefuku R, Yoshikawa K, Tsukimoto M, Owa H, Tamai Y, Tameda M, Ogura S, Sugimoto R, Tanaka H, Eguchi A, Sugimoto K, Hasegawa H, Iwasa M,Nakagawa H. A case of hepatocellular carcinoma seudoprogression involving the main portal vein, right ventricular invasion, and exacerbation of lung metastases in a patient on atezolizumab plus bevacizumab. Intern Med. 2022
2.Eguchi A, Iwasa M, Yamada M, Tamai Y, Shigefuku R, Hasegawa H, Hirokawa Y, Hayashi A, Okuno K, Matsushita Y, Nakatsuka T, Enooku K, Sakaguchi K, Kobayashi Y, Yamaguchi T, Watanabe M, Takei Y, Nakagawa H. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human NASH. Hepatology Communications. 2022 3.Tsukimoto M, Sugimoto K, Shigefuku R, Sugimoto R, Yuasa H, Uchida K, Yamamoto N. Recurrent hepatocellular carcinoma with osteoclast-like giant cells: a case report. J Med Case Rep. 2022 Apr 1;16(1):142. 4.Shigefuku R, Iwasa M, Eguchi A, Tempaku M, Tamai Y, Suzuki T, Takei Y. Serum Copeptin and Zinc-α2-glycoprotein Levels are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. Intern Med. 2021;60(21):3359-3368. 5.Shigefuku R, Iwasa M, Yoshikawa K, Takei Y. A Rare Presentation of Intraperitoneal Ectopic Varices Rupture. Intern Med. 2021 Mar 15;60(6):959-960. 6.Satta Y*, Shigefuku R* (*Co-first author), Watanabe T, Mizukami T, Tsuda T, Suzuki T, Ehira T, Hattori N, Kiyokawa H, Nakahara K, Ikeda H, Matsunaga K, Takahashi H, Matsumoto N, Okuse C, Suzuki M, Sunakawa Y, Yasuda H, Itoh F. JGH Open. 2021 Nov 2;5(11):1289-1297. 7.Iwasa M, Shigefuku R (Corresponding), Eguchi A, Tamai Y, Takei Y. Update on blood-based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience. JGH Open. 2021 Oct 30;5(11):1250-1256. 8.Suzuki T, Eguchi A, Shigefuku R, Nagao S, Morikawa M, Sugimoto K, Iwasa M, Takei Y. Accuracy of carbohydrate-deficient transferrin (CDT) as a biomarker of chronic alcohol abuse during treatment for alcoholism. Hepatol Res.2021 9.Shigefuku R, Iwasa M, Eguchi A, Tamai Y, Yoshikawa K, Sugimoto R, Takei Y. Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease. J Gastroenterol Hepatol. 2021Apr;36(4):1006-1014. 10.Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Kamada Y, Miyoshi E, Takei Y. Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy. JGH Open 2021 Jun 23;5(7):827-830. 11.Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Sugimoto K, Hasegawa H, Takei Y. Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma. PLoS One Aug 28;15(8):e0237370, 2020 12.Shigefuku R, Iwasa M, Katayama K, Eguchi A, Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, Ohtake T, Tokumoto Y, Endo R, Kawamura N, Shiraki M, Habu D, Sakai H, Kato A, Nishiguchi S, Moriwaki H, Suzuki K, Takei Y. Hypozincemia is associated with human hepatocarcinogenesis in hepatitis C virus-related liver cirrhosis. Hepatol Res. 49:1127-1135,2019 13.Shigefuku R, Watanabe T, Mizukami T, Matsunaga K, Hattori N, Ehira T, Suzuki T, Nakano H, Sato Y, Matsuo Y, Nakahara K, Ikeda H, Matsumoto N, Tsuda T, Katayama M, Koizumi S, Okuse C, Suzuki M, Otsubo T, Nakajima ET, Yasuda H, Itoh F. Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy. Clin J Gastroenterol. 11(6):487-492, 2018 14.Ikeda H, Watanabe T, Matsumoto N, Hiraishi T, Nakano H, Noguchi Y, Hattori N, Shigefuku R, Yamashita M, Nakahara K, Matsunaga K, Okuse C, Yotsuyanagi H, Tanaka A, Suzuki M, Itoh F. Daclatasvir and asunaprevir improves health-related quality of life in Japanese patients infected with hepatitis C virus. JGH Open. May 14;2(3):87-92, 2018 15.Shigefuku R, Watanabe T, Kanno Y, Ikeda H, Nakano H, Hattori N, Matsunaga K, Matsumoto N, Kanno SI, Nosho K, Hachiya A, Iwatani Y, Matsumori T, Tsukikawa S, Makizumi R, Otsubo T, Yamamoto H, Itoh F. Fusobacterium nucleatum detected simultaneously in a pyogenic liver abscess and advanced sigmoid colon cancer. Anaerobe. Aug 16;48:144-146, 2017 16.Hattori N, Ikeda H, Nakano H, Matsumoto N, Watanabe T, Shigefuku R, Noguchi Y, Matsunaga K, Sakai H, Okuse C, Yamamoto H, Miura I, Suzuki M, Itoh F. Curative Effects for B-Cell Lymphoma Accomplished by Direct-Acting Antiviral Agents of Hepatitis C. Open Forum Infect Dis. Mar 25;4(2):ofx057, 2017 17.Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H, Hiraishi T, Kobayashi M, Yasuda K, Yamamoto H, Yasuda H, Kurosaki M, Izumi N, Yotsuyanagi H, Suzuki M, Itoh F. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir. J Med Virol. 89:99-105, 2017 18.Shigefuku R, Takahashi H, Nakano H, Watanabe T, Matsunaga K, Kato M, Morita R, MichikawaY, Tamura T, Hiraishi T, Nobuhiro H, Noguchi Y, Nakahara K, Ikeda H, Ishii T, Matsumoto N, Okuse C, Sase S, Itoh F , Suzuki M. Correlation with hepatic hemodynamics, liver function and fibrotic markers in nonalcoholic fatty liver disease - Comparison with chronic hepatitis related to hepatitis C virus - Int. J. Mol. Sci. 14;17(9);1545, 2016 19.Ikeda H, Okuse C, Watanabe T, Matsumoto N, Matsunaga K, Shigefuku R, Hattori N, Hiraishi T, Fukuda Y, Noguchi Y, Ishii T, Shima J, Nakahara K, Yamamoto H, Yasuda H, Yotsuyanagi H, Koike K, Itoh F, Suzuki M. Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy? Turk J Gastroenterol. 27(2):165-72, 2016 20.Matsumoto N, Ikeda H, Shigefuku R, Hattori N, Watanabe T, Matsunaga K, Hiraishi T, Tamura T, Noguchi Y, Fukuda Y, Ishii T, Okuse C, Sato A, Suzuki M, Itoh F. Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. PLoS One. 18;11(3):e0151238 , 2016 21.Michikawa Y, Ikeda H, Okuse C, Okano M, Shigefuku R, Hattori N, Hatsugai M, Takahashi H, Matsunaga K, Watanabe T, Matsumoto N, Yotsuyanagi H, Suzuki M, Itoh F. Development of de novo hepatitis B in patient during follow-up of liver-graft-versus-host disease associated with allogeneic peripheral blood stem cell transplantation. Case Reports in Internal Medicine 3(1);16-20,2016 22.Matsumoto N, Ozawa S, Tamura T, Shigefuku R, Noguchi Y, Ikeda H, Matsunaga K, Okuse C, Suzuki M, Itoh F. Additional Malignant Transformation of a Hepatocelluar Carcinoma Cell Line by Heat Treatment Can Occur Through Epithelial-Mesenchymal Transiton without of Heat Resistance. J of St.Marianna Univ. 5 : 37-46, 2014 23.Shigefuku R※, Takahashi H※(※equally contributed), Yoshida Y, Ikeda H, Matsunaga K, Matsumoto N, Okuse C, Sase S, Maeyama S, Itoh F and Suzuki M. Correlation between Hepatic Blood Flow and liver Function In Alcoholic Liver Cirrhosis. World J Gastroenterol. 20(45) : 17065-17074, 2014 24.Shigefuku R, Takahashi H, Kato M, Yoshida Y, Suetani K, Noguchi Y, Hatsugai M, Nakahara K, Ikeda H, Kobayashi M, Matsunaga K, Matsumoto N, Okuse C, Itoh F, Maeyama S, Sase S and Suzuki M. Evaluation of Hepatic Tissue Blood Flow Using Xenon Computed Tomography with Fibrosis Progression in Nonalcoholic Fatty Liver Disease:Comparison with Chronic Hepatitis C. Int. J. Mol. Sci. 15 :1026-1039, 2014 25.Shigefuku R※, Takahashi H※ (※equally contributed), Maeyama S and Suzuki M. Cirrhosis improvement to alcoholic liver fibrosis after passive abstinence. BMJ Case Rep. 2014 Jan 10;2014:bcr2013201618. 26.Yamada N, Shigefuku R, Sugiyama R, Kobayashi M, Ikeda H, Takahashi H, Okuse C, Suzuki M, Itoh F, Yotsuyanagi H, Yasuda K, Moriya K, Koike K, Wakita T and Kato T. A Case of Acute Hepatitis B of Genotype H Resulting in Persistent Infection. World J Gastroenterol. 20(45) : 17065-17074, 2014 27.Saito T, Inoue Y, Sato K, Tsuruoka Y, Shigefuku R, Ikeda H, Okuse C, Takahashi M and Miura I. Improvement of high serum levels of biomarkers of endothelial injury after allogeneic hematopoietic SCT with pre-existing severe hepatitis using recombinant human soluble thrombomodulin. Bone Marrow Transplant. 1444-5, 2014 28.Shigefuku R, Takahashi H, Ikeda H, Matsunaga K, Koike J, Maeyama S, Matsumoto N, Okuse C, Itoh F and Suzuki M. Case of Nonalcoholic Steatohepatitis Occurring in Combination with Sleep Apnea Syndrome, Which Showed a Trend Toward Improvement of Liver Function by Introduction of Continuous Positive Airway Pressure. J Clin Case Rep. 3:10, 2013 29.Nakahara K, Okuse C, Suetani K, Morita R, Michikawa Y, Noguchi Y, Hattori N, Shigefuku R, Adachi S, Hatsugai M, Ikeda H, Takahashi H, Matsunaga K, Matsumoto N, Kobayashi S, Otsubo T, Itoh F. A Novel Endoscopic Papillectomy After a Pancreatic Stent Placement Above the Pancreatic Duct Orifice: Inside Pancreatic Stenting Papillectomy．J Clin Gastroenterol. 48(9):796-800, 2014 30.Nakahara K, Okuse C, Adachi S, Suetani K, Kitagawa S, Okano M, Michikawa Y, Takagi R, Shigefuku R, Itoh F．Use of Antithrombin and Thrombomodulin in the Management of Disseminated Intravascular Coagulation in Patients with Acute Cholangitis. Gut Liver 7 : 363-370, 2013 31.Takahashi H, Suzuki M, Shigefuku R, Okano M, Hiraishi T, Takagi R, Noguchi Y, Hattori N, Hatsugai M, Nakahara K, Okamoto M, Kobayashi M, Ikeda H, Fukuda Y, Nagase Y, Ishii T, Matsunaga K, Matsumoto N, Okuse C, Sase S, Itoh F. Xenon computed tomography can evaluate the improvement of hepatic hemodynamics before and after endoscopic injection sclerotherapy. J Gastroenterol.48 : 1353-1361, 2013 32.Matsunaga K, Suzuki M, Matsumoto N, Yamada N, Kobayashi M, Shigefuku R, Hattori N, Kou S, Okamoto M, Ikeda H, Fukuda Y, Nagase Y, Takahashi H, Baba S, Ishii T, Okuse C, Yotsuyanagi H, Yasuda K, Itoh F. Stricter Control of Alanine Transaminase by Long-term Administration of Glycyrrhizin Counters the Disease Progression in Patients with Chronic Hepatitis C. J of St.Marianna Univ. 3 : 23-33, 2012 33.Sase S, Takahashi H, Shigefuku R, Ikeda H, Kobayashi M, Matsumoto N, Suzuki M. Measurement of blood flow and xenon solubility coefficient in the human liver by xenon-enhanced computed tomography. Med. Phys. 39 (12)：7553-7559, 2012 34.Shigefuku R, Takahashi H, Kobayashi M, Ikeda H, Matsunaga K, Okuse C, Matsumoto M, Maeyama S, Sase S, Suzuki M, Itoh F. Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis? J Gastroenterol.47 : 1238-1247, 2012 35.Nakahara K, Takahashi H, Okuse C, Shigefuku R, Yamada N, Murao M, Matsunaga K, Koike J, Yotsuyanagi H, Suzuki M, Kimura K, Itoh F. Membranous Nephropathy Associated with Chronic Hepatitis B Occurring in a Short Period After Acute Hepatitis B Virus Infection. Intern Med. 49 : 383-388, 2010 |
|||||||||